Amgen (AMGN): Little Impact Expected From Parsabiv Rejection - Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall St slips as higher yields offset upbeat corporate earnings
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices fall as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Jefferies Says No Changes to Ests on Amgen (AMGN) Amid Parsabiv CRL; Affirms at 'Buy'
August 25, 2016 7:43 AM EDTJefferies affirms Amgen (Nasdaq: AMGN) with a Buy rating and $198 price target following receipt of FDA CRL on Parsabiv.
The firm commented, On positive Ph3 data, FDA approval of Parsabiv for treatment of secondary hyperparathyroidism was largely expected. Details of the CRL is... More
